Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer

This trial is testing the diagnostic accuracy and safety of a radioactive PET scan tracer called Flotufolastat F-18 (XTR020), which targets a protein found on prostate cancer cells (PSMA). It is being studied in men whose PSA levels have risen again after initial prostate cancer treatment, suggesting the cancer may have returned. **You may be eligible if...** - You are male, 18 or older - You have previously been treated for prostate cancer (surgery, radiation, or other local therapy) - Your PSA level has risen in a way that suggests cancer recurrence - You are willing to follow up with a biopsy or additional imaging if a lesion is detected **You may NOT be eligible if...** - You are planning to have another radioactive imaging scan within 24 hours before this study's PET scan - You are currently enrolled in an interventional clinical trial - You are unable to follow contraception requirements during the study Talk to your doctor to see if this trial is right for you.